Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Press releaseGlobeNewswire· November 27, 2025
CD38-Targeted Immunotherapies Pipeline and Competitive Intelligence Report 2025: Darzalex Became the Number 4 Blockbuster Biologic, Just Behind Keytruda, Dupixent and Skyrizi
View original at globenewswire.comCD38-Targeted Immunotherapies Pipeline and Competitive Intelligence Report 2025: Darzalex Became the Number 4 Blockbuster Biologic, Just Behind Keytruda, Dupixent and Skyrizi Dublin, Nov…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
CD38 is an attractive target for antibody therapy because it is highly expressed on malignant plasma cells
100% confidenceCD38 is a clinically validated and commercially very successful target
100% confidenceMultiple Myeloma represents the second most frequent hematological malignancy, accounting 1% of all cancer and 13% of hematological tumors
100% confidenceThe patent holder of Darzalex expects that royalties from sales of DARZALEX will begin to decline materially in 2029 following expiration of U.S. patent rights on daratumumab
95% confidence
